Astrazeneca (AZN) Total Debt (2009 - 2026)

Astrazeneca's Total Debt history runs 18 years deep, the most recent figure standing at -$24.5 billion for Q1 2026.

• In Q1 2026, Total Debt rose 8.38% year-over-year to -$24.5 billion; the TTM figure through Mar 2026 stood at -$24.5 billion (up 8.38% YoY), while the FY2025 annual figure was -$21.6 billion, down 174.93% from the prior year.
• Total Debt was -$24.5 billion for Q1 2026 at Astrazeneca, down from -$21.6 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $28.8 billion in Q4 2024 to a low of -$28.9 billion in Q3 2024.
• Historically, Total Debt has averaged -$16.0 billion across 5 years, with a median of -$24.7 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Debt grew 18.41% in 2022, then sank 174.93% in 2025.
• A 5-year view of Total Debt shows it stood at $28.3 billion in 2022, then fell by 2.78% to $27.5 billion in 2023, then grew by 4.91% to $28.8 billion in 2024, then plunged by 174.93% to -$21.6 billion in 2025, then dropped by 13.16% to -$24.5 billion in 2026.
• The last three Total Debt figures came in at -$24.5 billion (Q1 2026), -$21.6 billion (Q4 2025), and -$24.7 billion (Q3 2025), per Business Quant data.